Marks the Third Year Since the Launch of the First US Biosimilar Market ReportINCHEON, South Korea, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Samsung ...

Formycon and Fresenius Kabi secure UK approval for Otulfi, a ustekinumab biosimilar targeting inflammatory conditions.

The sequence of biologic treatments in patients with inflammatory bowel disease significantly affects their risk of adverse ...

Formycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® Otulfi ® received MHRA approval for both subcutaneous and intravenous formulations, to ...

Regulatory ApprovalFormycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® 15.01.2025 / 06:30 CET/CESTThe issuer is solely responsible for the ...

Bengaluru: Biocon has announced that the U.S. Food and Drug Administration (FDA) has classified Biocon Biologics' Insulins ...

Biocon shares increased by 4.5% after the US FDA classified its Malaysian insulin facilities as Voluntary Action Indicated.

Adalimumab and secukinumab are the only FDA-approved biologic drugs to treat hidradenitis suppurativa, limiting options for ...

The efficacy and safety of a proposed biosimilar and ustekinumab are similar among adults with moderate to severe plaque psoriasis.

Indian equity markets closed lower past week, with the NIFTY down by 573 points or 2.39% and the Sensex down by 2.33%. But ...

Approved by Health Canada for Both Subcutaneous and Intravenous Formulations to Treat Serious Inflammatory Diseases Health Canada Joins the FDA and the European Commission in Granting Regulatory ...

Bio-Thera Solutions Inc. announced that it has partnered with Tabuk Pharmaceutical Manufacturing Company to commercialize BAT2206, ...